TABLE 3.
ACE2 (rs2285666) and TMPRSS2 (rs12329760) gene polymorphisms in patients’ groups and the controls.
| Variables | Control | Mild COVID-19 | OR (CI 95%) | Moderate COVID-19 | OR (CI 95%) | Severe COVID-19 | OR (CI 95%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No | % | No | % | No | % | No | % | ||||
| ACE2 (rs2285666) | |||||||||||
| CC | 114 | 77.6 | 91 | 78.4 | 1.0 (Ref.) | 74 | 57.8 | 1.0 | 31 | 56.4 | 1.0 |
| CT | 21 | 14.3 | 12 | 10.3 | 0.72 (0.33–1.53) | 0 | 0.0 | - | 10 | 18.2 | 1.75 (0.75–4.10)* |
| TT | 12 | 8.2 | 13 | 11.2 | 1.36 (0.59–3.12) | 54 | 42.2 | 6.93 (3.48–13.83)* | 14 | 25.5 | 4.29 (1.80–10.21)* |
| Alleles | |||||||||||
| C | 249 | 84.7 | 194 | 83.6 | 1.0 (Ref.) | 148 | 57.8 | 1.0 | 72 | 65.5 | 1.0 |
| T | 45 | 13.3 | 38 | 16.4 | 1.08 (0.68–1.74) | 108 | 42.2 | 4.04 (2.70–6.04)* | 38 | 34.5 | 2.92 (1.76–4.84)* |
| TMPRSS2 (rs12329760) | |||||||||||
| CC | 123 | 83.7 | 98 | 84.5 | 1.0 (Ref.) | 107 | 83.6 | 1.0 | 31 | 56.4 | 1.0 |
| CT | 21 | 14.3 | 15 | 12.9 | 0.90 (0.44–1.83) | 21 | 16.4 | 1.15 (0.60–2.22) | 15 | 27.3 | 2.83 (1.31–6.13)* |
| TT | 3 | 2.0 | 3 | 2.6 | 1.26 (0.25–6.36) | 0 | 0.0 | - | 9 | 16.4 | 11.90 (3.04–46.60) |
| Alleles | |||||||||||
| C | 267 | 90.8 | 211 | 90.9 | 1.0 (Ref.) | 235 | 91.8 | 1.0 | 77 | 70.0 | 1.0 |
| T | 27 | 9.2 | 21 | 9.1 | 0.98 (0.54–1.79) | 21 | 8.2 | 0.88 (0.49–1.60) | 33 | 30.0 | 4.24 (2.40–7.48)* |
*p < 0.05.
OR, Odd’s Ratio; CI, confidence interval; ACE2, Angiotensin-converting enzyme 2; TMPRSS2, Transmembrane serine protease 2; C, cytosine; T, thymine; Ref, Reference.